United Rail, Inc.
United Rail, Inc. (URAL) Stock Competitors & Peer Comparison
See (URAL) competitors and their performances in Stock Market.
Peer Comparison Table: Railroads Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| URAL | $0.00 | +0.00% | 52 | N/A | -$62,062.06 | N/A |
| MTRJF | $4.55 | +0.00% | 28.3B | 12.64 | $0.36 | +3.68% |
| CJPRF | $29.25 | +0.00% | 27.9B | 8.15 | $3.59 | +0.71% |
| MTCPY | $12.88 | +0.00% | 26.7B | 14.31 | $0.90 | +3.89% |
| EJPRY | $11.59 | -2.52% | 26.3B | 16.86 | $0.69 | +2.77% |
| EJPRF | $21.31 | +0.00% | 24.1B | 16.65 | $1.28 | +2.26% |
| CJPRY | $11.07 | -1.25% | 21.1B | 6.15 | $1.80 | +1.22% |
| VOSSY | $8.40 | +0.00% | 16.2B | 30.00 | $0.28 | +1.61% |
| GRPTF | $21.50 | +0.00% | 11.7B | 31.16 | $0.69 | +3.07% |
| GRPTY | $41.96 | +0.00% | 11.4B | 30.41 | $1.38 | +3.14% |
Stock Comparison
URAL vs MTRJF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, MTRJF has a market cap of 28.3B. Regarding current trading prices, URAL is priced at $0.00, while MTRJF trades at $4.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas MTRJF's P/E ratio is 12.64. In terms of profitability, URAL's ROE is +0.03%, compared to MTRJF's ROE of +0.07%. Regarding short-term risk, URAL is more volatile compared to MTRJF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check MTRJF's competition here
URAL vs CJPRF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, CJPRF has a market cap of 27.9B. Regarding current trading prices, URAL is priced at $0.00, while CJPRF trades at $29.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas CJPRF's P/E ratio is 8.15. In terms of profitability, URAL's ROE is +0.03%, compared to CJPRF's ROE of +0.11%. Regarding short-term risk, URAL is more volatile compared to CJPRF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check CJPRF's competition here
URAL vs MTCPY Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, MTCPY has a market cap of 26.7B. Regarding current trading prices, URAL is priced at $0.00, while MTCPY trades at $12.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas MTCPY's P/E ratio is 14.31. In terms of profitability, URAL's ROE is +0.03%, compared to MTCPY's ROE of +0.07%. Regarding short-term risk, URAL is more volatile compared to MTCPY. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check MTCPY's competition here
URAL vs EJPRY Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, EJPRY has a market cap of 26.3B. Regarding current trading prices, URAL is priced at $0.00, while EJPRY trades at $11.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas EJPRY's P/E ratio is 16.86. In terms of profitability, URAL's ROE is +0.03%, compared to EJPRY's ROE of +0.08%. Regarding short-term risk, URAL is more volatile compared to EJPRY. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check EJPRY's competition here
URAL vs EJPRF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, EJPRF has a market cap of 24.1B. Regarding current trading prices, URAL is priced at $0.00, while EJPRF trades at $21.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas EJPRF's P/E ratio is 16.65. In terms of profitability, URAL's ROE is +0.03%, compared to EJPRF's ROE of +0.08%. Regarding short-term risk, URAL is more volatile compared to EJPRF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check EJPRF's competition here
URAL vs CJPRY Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, CJPRY has a market cap of 21.1B. Regarding current trading prices, URAL is priced at $0.00, while CJPRY trades at $11.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas CJPRY's P/E ratio is 6.15. In terms of profitability, URAL's ROE is +0.03%, compared to CJPRY's ROE of +0.11%. Regarding short-term risk, URAL is more volatile compared to CJPRY. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check CJPRY's competition here
URAL vs VOSSY Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, VOSSY has a market cap of 16.2B. Regarding current trading prices, URAL is priced at $0.00, while VOSSY trades at $8.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas VOSSY's P/E ratio is 30.00. In terms of profitability, URAL's ROE is +0.03%, compared to VOSSY's ROE of +0.08%. Regarding short-term risk, URAL is more volatile compared to VOSSY. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check VOSSY's competition here
URAL vs GRPTF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, GRPTF has a market cap of 11.7B. Regarding current trading prices, URAL is priced at $0.00, while GRPTF trades at $21.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas GRPTF's P/E ratio is 31.16. In terms of profitability, URAL's ROE is +0.03%, compared to GRPTF's ROE of +0.12%. Regarding short-term risk, URAL is more volatile compared to GRPTF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check GRPTF's competition here
URAL vs GRPTY Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, GRPTY has a market cap of 11.4B. Regarding current trading prices, URAL is priced at $0.00, while GRPTY trades at $41.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas GRPTY's P/E ratio is 30.41. In terms of profitability, URAL's ROE is +0.03%, compared to GRPTY's ROE of +0.12%. Regarding short-term risk, URAL is more volatile compared to GRPTY. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check GRPTY's competition here
URAL vs AOMFF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, AOMFF has a market cap of 9.5B. Regarding current trading prices, URAL is priced at $0.00, while AOMFF trades at $20.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas AOMFF's P/E ratio is 29.49. In terms of profitability, URAL's ROE is +0.03%, compared to AOMFF's ROE of +0.03%. Regarding short-term risk, URAL is more volatile compared to AOMFF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check AOMFF's competition here
URAL vs ALSMY Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, ALSMY has a market cap of 8.8B. Regarding current trading prices, URAL is priced at $0.00, while ALSMY trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas ALSMY's P/E ratio is 27.30. In terms of profitability, URAL's ROE is +0.03%, compared to ALSMY's ROE of +0.03%. Regarding short-term risk, URAL is more volatile compared to ALSMY. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check ALSMY's competition here
URAL vs WJRYF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, WJRYF has a market cap of 7.8B. Regarding current trading prices, URAL is priced at $0.00, while WJRYF trades at $17.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas WJRYF's P/E ratio is 9.85. In terms of profitability, URAL's ROE is +0.03%, compared to WJRYF's ROE of +0.14%. Regarding short-term risk, URAL is more volatile compared to WJRYF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check WJRYF's competition here
URAL vs WJRYY Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, WJRYY has a market cap of 7.8B. Regarding current trading prices, URAL is priced at $0.00, while WJRYY trades at $17.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas WJRYY's P/E ratio is 9.74. In terms of profitability, URAL's ROE is +0.03%, compared to WJRYY's ROE of +0.11%. Regarding short-term risk, URAL is more volatile compared to WJRYY. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check WJRYY's competition here
URAL vs CRYYF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, CRYYF has a market cap of 7.4B. Regarding current trading prices, URAL is priced at $0.00, while CRYYF trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas CRYYF's P/E ratio is 9.28. In terms of profitability, URAL's ROE is +0.03%, compared to CRYYF's ROE of +0.08%. Regarding short-term risk, URAL is more volatile compared to CRYYF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check CRYYF's competition here
URAL vs RUMOF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, RUMOF has a market cap of 7.1B. Regarding current trading prices, URAL is priced at $0.00, while RUMOF trades at $3.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas RUMOF's P/E ratio is 54.29. In terms of profitability, URAL's ROE is +0.03%, compared to RUMOF's ROE of +0.08%. Regarding short-term risk, URAL is more volatile compared to RUMOF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check RUMOF's competition here
URAL vs ZHUZY Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, ZHUZY has a market cap of 6.1B. Regarding current trading prices, URAL is priced at $0.00, while ZHUZY trades at $22.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas ZHUZY's P/E ratio is 10.07. In terms of profitability, URAL's ROE is +0.03%, compared to ZHUZY's ROE of +0.10%. Regarding short-term risk, URAL is more volatile compared to ZHUZY. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check ZHUZY's competition here
URAL vs GMXTF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, GMXTF has a market cap of 5.4B. Regarding current trading prices, URAL is priced at $0.00, while GMXTF trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas GMXTF's P/E ratio is 10.25. In terms of profitability, URAL's ROE is +0.03%, compared to GMXTF's ROE of +0.12%. Regarding short-term risk, URAL is more volatile compared to GMXTF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check GMXTF's competition here
URAL vs ZHUZF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, ZHUZF has a market cap of 5B. Regarding current trading prices, URAL is priced at $0.00, while ZHUZF trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas ZHUZF's P/E ratio is 10.43. In terms of profitability, URAL's ROE is +0.03%, compared to ZHUZF's ROE of +0.10%. Regarding short-term risk, URAL is more volatile compared to ZHUZF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check ZHUZF's competition here
URAL vs QRNNF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, QRNNF has a market cap of 4.6B. Regarding current trading prices, URAL is priced at $0.00, while QRNNF trades at $2.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas QRNNF's P/E ratio is 21.23. In terms of profitability, URAL's ROE is +0.03%, compared to QRNNF's ROE of +0.07%. Regarding short-term risk, URAL is more volatile compared to QRNNF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check QRNNF's competition here
URAL vs CRYCY Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, CRYCY has a market cap of 4.6B. Regarding current trading prices, URAL is priced at $0.00, while CRYCY trades at $4.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas CRYCY's P/E ratio is 8.75. In terms of profitability, URAL's ROE is +0.03%, compared to CRYCY's ROE of +0.08%. Regarding short-term risk, URAL is more volatile compared to CRYCY. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check CRYCY's competition here
URAL vs BKKXF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, BKKXF has a market cap of 4.3B. Regarding current trading prices, URAL is priced at $0.00, while BKKXF trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas BKKXF's P/E ratio is N/A. In terms of profitability, URAL's ROE is +0.03%, compared to BKKXF's ROE of +0.10%. Regarding short-term risk, URAL is more volatile compared to BKKXF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check BKKXF's competition here
URAL vs KELRF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, KELRF has a market cap of 4B. Regarding current trading prices, URAL is priced at $0.00, while KELRF trades at $8.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas KELRF's P/E ratio is 8.84. In terms of profitability, URAL's ROE is +0.03%, compared to KELRF's ROE of +0.09%. Regarding short-term risk, URAL is more volatile compared to KELRF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check KELRF's competition here
URAL vs ODERF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, ODERF has a market cap of 3.9B. Regarding current trading prices, URAL is priced at $0.00, while ODERF trades at $11.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas ODERF's P/E ratio is 14.62. In terms of profitability, URAL's ROE is +0.03%, compared to ODERF's ROE of +0.09%. Regarding short-term risk, URAL is more volatile compared to ODERF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check ODERF's competition here
URAL vs TBURF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, TBURF has a market cap of 3.2B. Regarding current trading prices, URAL is priced at $0.00, while TBURF trades at $16.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas TBURF's P/E ratio is 10.99. In terms of profitability, URAL's ROE is +0.03%, compared to TBURF's ROE of +0.09%. Regarding short-term risk, URAL is more volatile compared to TBURF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check TBURF's competition here
URAL vs SRAIF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, SRAIF has a market cap of 2.7B. Regarding current trading prices, URAL is priced at $0.00, while SRAIF trades at $27.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas SRAIF's P/E ratio is 24.25. In terms of profitability, URAL's ROE is +0.03%, compared to SRAIF's ROE of +0.11%. Regarding short-term risk, URAL is more volatile compared to SRAIF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check SRAIF's competition here
URAL vs GNGYF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, GNGYF has a market cap of 2.6B. Regarding current trading prices, URAL is priced at $0.00, while GNGYF trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas GNGYF's P/E ratio is 9.67. In terms of profitability, URAL's ROE is +0.03%, compared to GNGYF's ROE of +0.06%. Regarding short-term risk, URAL is more volatile compared to GNGYF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check GNGYF's competition here
URAL vs CDGLF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, CDGLF has a market cap of 2.4B. Regarding current trading prices, URAL is priced at $0.00, while CDGLF trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas CDGLF's P/E ratio is 13.76. In terms of profitability, URAL's ROE is +0.03%, compared to CDGLF's ROE of +0.09%. Regarding short-term risk, URAL is more volatile compared to CDGLF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check CDGLF's competition here
URAL vs CDGLY Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, CDGLY has a market cap of 2.1B. Regarding current trading prices, URAL is priced at $0.00, while CDGLY trades at $19.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas CDGLY's P/E ratio is 11.96. In terms of profitability, URAL's ROE is +0.03%, compared to CDGLY's ROE of +0.09%. Regarding short-term risk, URAL is more volatile compared to CDGLY. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check CDGLY's competition here
URAL vs JFBHF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, JFBHF has a market cap of 1.9B. Regarding current trading prices, URAL is priced at $0.00, while JFBHF trades at $324.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas JFBHF's P/E ratio is 18.76. In terms of profitability, URAL's ROE is +0.03%, compared to JFBHF's ROE of +0.10%. Regarding short-term risk, URAL is more volatile compared to JFBHF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check JFBHF's competition here
URAL vs VOSSF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, VOSSF has a market cap of 1.5B. Regarding current trading prices, URAL is priced at $0.00, while VOSSF trades at $77.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas VOSSF's P/E ratio is 27.82. In terms of profitability, URAL's ROE is +0.03%, compared to VOSSF's ROE of +0.09%. Regarding short-term risk, URAL is more volatile compared to VOSSF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check VOSSF's competition here
URAL vs FGROF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, FGROF has a market cap of 1.3B. Regarding current trading prices, URAL is priced at $0.00, while FGROF trades at $2.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas FGROF's P/E ratio is 8.21. In terms of profitability, URAL's ROE is +0.03%, compared to FGROF's ROE of +0.19%. Regarding short-term risk, URAL is more volatile compared to FGROF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check FGROF's competition here
URAL vs BTGRF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, BTGRF has a market cap of 1.2B. Regarding current trading prices, URAL is priced at $0.00, while BTGRF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas BTGRF's P/E ratio is 7.41. In terms of profitability, URAL's ROE is +0.03%, compared to BTGRF's ROE of -0.02%. Regarding short-term risk, URAL is more volatile compared to BTGRF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check BTGRF's competition here
URAL vs FGROY Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, FGROY has a market cap of 1.2B. Regarding current trading prices, URAL is priced at $0.00, while FGROY trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas FGROY's P/E ratio is 7.45. In terms of profitability, URAL's ROE is +0.03%, compared to FGROY's ROE of +0.19%. Regarding short-term risk, URAL is more volatile compared to FGROY. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check FGROY's competition here
URAL vs BTSGY Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, BTSGY has a market cap of 495.7M. Regarding current trading prices, URAL is priced at $0.00, while BTSGY trades at $3.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas BTSGY's P/E ratio is 6.55. In terms of profitability, URAL's ROE is +0.03%, compared to BTSGY's ROE of -0.02%. Regarding short-term risk, URAL is more volatile compared to BTSGY. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check BTSGY's competition here
URAL vs GRPOF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, GRPOF has a market cap of 421.5M. Regarding current trading prices, URAL is priced at $0.00, while GRPOF trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas GRPOF's P/E ratio is 18.95. In terms of profitability, URAL's ROE is +0.03%, compared to GRPOF's ROE of +0.02%. Regarding short-term risk, URAL is less volatile compared to GRPOF. This indicates potentially lower risk in terms of short-term price fluctuations for URAL.Check GRPOF's competition here
URAL vs GLTVF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, GLTVF has a market cap of 321M. Regarding current trading prices, URAL is priced at $0.00, while GLTVF trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas GLTVF's P/E ratio is 1.50. In terms of profitability, URAL's ROE is +0.03%, compared to GLTVF's ROE of +0.01%. Regarding short-term risk, URAL is more volatile compared to GLTVF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check GLTVF's competition here
URAL vs NXPGF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, NXPGF has a market cap of 189.2M. Regarding current trading prices, URAL is priced at $0.00, while NXPGF trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas NXPGF's P/E ratio is -0.17. In terms of profitability, URAL's ROE is +0.03%, compared to NXPGF's ROE of +1.60%. Regarding short-term risk, URAL is more volatile compared to NXPGF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check NXPGF's competition here
URAL vs DMRRP Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, DMRRP has a market cap of 2.9M. Regarding current trading prices, URAL is priced at $0.00, while DMRRP trades at $60.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas DMRRP's P/E ratio is N/A. In terms of profitability, URAL's ROE is +0.03%, compared to DMRRP's ROE of N/A. Regarding short-term risk, URAL is more volatile compared to DMRRP. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check DMRRP's competition here
URAL vs AWRY Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, AWRY has a market cap of 2.3M. Regarding current trading prices, URAL is priced at $0.00, while AWRY trades at $72.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas AWRY's P/E ratio is N/A. In terms of profitability, URAL's ROE is +0.03%, compared to AWRY's ROE of N/A. Regarding short-term risk, URAL is more volatile compared to AWRY. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check AWRY's competition here
URAL vs DMRR Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, DMRR has a market cap of 1.7M. Regarding current trading prices, URAL is priced at $0.00, while DMRR trades at $35.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas DMRR's P/E ratio is N/A. In terms of profitability, URAL's ROE is +0.03%, compared to DMRR's ROE of N/A. Regarding short-term risk, URAL is more volatile compared to DMRR. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check DMRR's competition here
URAL vs USDP Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, USDP has a market cap of 101.3K. Regarding current trading prices, URAL is priced at $0.00, while USDP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas USDP's P/E ratio is 0.30. In terms of profitability, URAL's ROE is +0.03%, compared to USDP's ROE of +0.44%. Regarding short-term risk, URAL is less volatile compared to USDP. This indicates potentially lower risk in terms of short-term price fluctuations for URAL.Check USDP's competition here
URAL vs MAGP Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, MAGP has a market cap of 18.7K. Regarding current trading prices, URAL is priced at $0.00, while MAGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas MAGP's P/E ratio is N/A. In terms of profitability, URAL's ROE is +0.03%, compared to MAGP's ROE of +0.00%. Regarding short-term risk, URAL is less volatile compared to MAGP. This indicates potentially lower risk in terms of short-term price fluctuations for URAL.Check MAGP's competition here
URAL vs RLPHQ Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, RLPHQ has a market cap of 9.1K. Regarding current trading prices, URAL is priced at $0.00, while RLPHQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas RLPHQ's P/E ratio is -0.00. In terms of profitability, URAL's ROE is +0.03%, compared to RLPHQ's ROE of N/A. Regarding short-term risk, URAL is less volatile compared to RLPHQ. This indicates potentially lower risk in terms of short-term price fluctuations for URAL.Check RLPHQ's competition here
URAL vs BVZHF Comparison May 2026
URAL plays a significant role within the Industrials sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, URAL stands at 52. In comparison, BVZHF has a market cap of 0. Regarding current trading prices, URAL is priced at $0.00, while BVZHF trades at $792.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
URAL currently has a P/E ratio of N/A, whereas BVZHF's P/E ratio is 42.13. In terms of profitability, URAL's ROE is +0.03%, compared to BVZHF's ROE of +0.10%. Regarding short-term risk, URAL is more volatile compared to BVZHF. This indicates potentially higher risk in terms of short-term price fluctuations for URAL.Check BVZHF's competition here